5 results
IDSA Recommendations for Preventing and Treating HHV-8 Diseases—Kaposi Sarcoma (KS), Primary Effusion Lymphoma (PEL), Multicentric Castleman’s
, Multicentric Castleman ... Disease (MCD) in HIV-AIDS ... #Treatment #management ... opportunistic #infections ... #HIVAIDS #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
Candidiasis in HIV-AIDS ... mucosal #IDSA #Prevention ... #Treatment #management ... opportunistic #infections ... #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Cryptococcosis in HIV-AIDS
Treatment for cryptococcosis consists of 3 phases: induction,
Recommendations for Preventing ... in HIV-AIDS Treatment ... #Treatment #management ... opportunistic #infections ... #HIVAIDS #pharmacology
IDSA Recommendations for Treating Coccidiodomycosis in HIV-AIDS
Treating Mild Infections (Such As Focal Pneumonia or asymptomatic patients
Coccidiodomycosis in HIV-AIDS ... (Diffuse Pulmonary ... Coccidiodomycosis #IDSA #Prevention ... #Treatment #management ... #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Disseminated Mycobacterium Avium Complex in HIV-AIDS
Preventing 1st Episode of Disseminated
Avium Complex in HIV-AIDS ... Mycobacterium #AviumComplex ... #Treatment #management ... opportunistic #infections ... #HIVAIDS #pharmacology